Promoting tuberculosis preventive therapy in HIV

Lancet HIV. 2022 Sep;9(9):e596-e597. doi: 10.1016/S2352-3018(22)00197-7. Epub 2022 Jul 28.

Authors

Sylvia M LaCourse¹, Dickens Onyango²

Affiliations

¹ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98104, USA; Department of Global Health, University of Washington, Seattle, WA, USA. Electronic address: sylvial2@uw.edu.
² Kisumu County Department of Health, Kisumu, Kenya; Julius Global Health, Julius Centre for Health Sciences and Primary Care, University Medical Centre, Utrecht, Netherlands.

PMID: 35908552
DOI: 10.1016/S2352-3018(22)00197-7

No abstract available

Publication types

Comment

MeSH terms

Antitubercular Agents / therapeutic use
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Isoniazid
Tuberculosis* / drug therapy
Tuberculosis* / epidemiology
Tuberculosis* / prevention & control

Substances

Antitubercular Agents
Isoniazid